Introduction
Members of the B-cell lymphoma-2 (Bcl-2) protein family play important roles in the regulation of cellular apoptosis, and exhibit either anti-or proapoptotic function. Antiapoptotic members of the Bcl-2 protein family include Bcl-2, Bcl-X L , myeloid cell leukemia-1 (Mcl-1), Bcl-w, Bfl-1/A1, Bcl-b, and Bcl-2-L-10, while proapoptotic activity is exhibited by Bax, Bak, Bad, Bid, Bcl-X S , Mcl-1S, Bok/Mtd, and Bik/Nbk (Figure 1 ). Bcl-2, the prototypic antiapoptotic member, was first identified based on translocation of the bcl-2 gene into the immunoglobulin locus (t14;18)(q32;q21) in 85-90% of follicular B-cell lymphomas.
1,2 The Bcl-2 oncoprotein exerts its oncogenic effects by inhibiting apoptosis in cells that are normally destined for death, thereby promoting the accumulation of cells in vivo. [3] [4] [5] Gene transfer studies have shown that Bcl-2 can inhibit cell death resulting from a wide variety of apoptotic stimuli, including chemotherapy drugs, [6] [7] [8] radiation, 9, 10 and growth factor withdrawal. 3, 11 Similarly, Bcl-X L (Bcl-X L is produced from the long alternative splice form of the bcl-x gene, while proapoptotic Bcl-X S is derived from the short alternative splice form of this gene) renders cells refractory to treatment with diverse proapoptotic stimuli. 12 Mcl-1 is prominently expressed during myeloid cell differentiation, 13, 14 and is known to perform cell death-inhibitory functions under a variety of conditions. 15 In contrast to antiapoptotic proteins, proapoptotic members of the Bcl-2 protein family activate cell death signaling, promoting a reduction in cell numbers. It is likely that within a given cell, the delicate balance between pro-and antiapoptotic molecules serves to determine whether the cell will live or die. 16 Therefore, it is not surprising that aberrant expression of Bcl-2 family members is a hallmark of many cancers. An abundance of antiapoptotic proteins, such as Bcl-2 and Bcl-X L , or altered ratios between pro-and antiapoptotic proteins is commonly found in human malignancies. In many cancers, the overexpression of death-inhibitory proteins has been directly linked to poor prognosis and resistance to conventional forms of therapies. In view of this, strategies aimed at inhibiting the expression or function of antiapoptotic proteins offer considerable therapeutic promise. Conceivably, agents that selectively target antiapoptotic molecules may have tremendous value in enhancing the chemosensitivity of apoptosis-resistant malignancies. This review will discuss current approaches for targeting the expression and function of Bcl-2 and Bcl-X L .
Deregulated expression of Bcl-2 and Bcl-X L in human malignancies
Overexpression of the Bcl-2 oncoprotein has been reported in cancers of both hematological and nonhematological origin. In particular, elevated levels of Bcl-2 are frequently detected in leukemias and lymphomas. A large number of studies have reported overexpression of Bcl-2 in acute myeloid leukemia (AML), [17] [18] [19] [20] [21] [22] where overexpression or an increased Bcl-2/Bax ratio is associated with poor clinical response. 17, [21] [22] [23] The t(14;18)(q32;q21) translocation is frequently found in B-cell malignancies such as follicular lymphomas, and leads to increased expression of wild-type Bcl-2 protein. Bcl-2 overexpression is found in most cases of adult, but not pediatric, follicular lymphoma. 24, 25 Although, the t(14;18) translocation is less common (o10% of cases) in B-CLL, [26] [27] [28] Bcl-2 overexpression has been observed in this disease, and is linked to poor prognosis. [29] [30] [31] [32] In addition, an increased ratio of Bcl-2/Bax has been correlated with B-CLL advancement. [33] [34] [35] It has been proposed that the increased levels of Bcl-2 in B-CLL may be attributable to hypomethylation of the Bcl-2 promoter. 29 In large B-cell non-Hodgkin's lymphoma, multiple myeloma, or anaplastic large cell lymphoma (ALCL), overexpression of Bcl-2, or an increased number of Bcl-2-positive cells, correlated with poor prognosis. [36] [37] [38] [39] Additionally, numerous studies have demonstrated Bcl-2 overexpression, and a correlation with poor prognosis, in nonhematological cancers, such as melanoma, 40 Bcl-X L has also been implicated in the pathogenesis of several types of cancer. While coexpression of Bcl-2 and Bcl-X L is seen in some cancers, or a particular stage of disease, other cancers exhibit exclusive expression of one or the other protein.
Increased expression of Bcl-X L 59 or an increased ratio of Bcl-X L /Bcl-X S 60 has been reported in AML patients with poor prognosis. In multiple myeloma patients, expression of Bcl-X L in plasma cells was found to correlate with decreased response to chemotherapy. 61 Advanced and relapsed cases of multiple myeloma are characterized by high levels of Bcl-X L ; 61 earlier stages of the disease manifest higher levels of Bcl-2. 38 In nonhematological cancers, elevated levels of Bcl-X L were detected in bladder transitional cell carcinoma, 62 and squamous cell cancer of the oropharynx, and correlated with poor remission after radiotherapy. 63 Both Bcl-X L and Bcl-2 are expressed in breast cancers. [43] [44] [45] [46] 64 In pancreatic cancer, although Bcl-2 has not demonstrated prognostic significance, 65 overexpression of Bcl-X L is associated with shorter patient survival. 66, 67 Both Bcl-2 and Bcl-X L are expressed in malignant melanoma and their levels increase with progression of the disease. 68, 69 In contrast to our current understanding of Bcl-2 and Bcl-X L , considerably less is known about the role of other antiapoptotic Bcl-2 family members in human malignancies. However, elevated levels of Mcl-1 have been reported in relapse cases of AML and ALL. 70 In addition, expression of Mcl-1 in B-CLL is negatively correlated with the ability of patients to achieve complete remission. 71 In multiple myeloma, Mcl-1 plays an important role in the survival of the malignant cells. 72 Expression of Mcl-1, but not Bcl-2 or Bcl-X L , is associated with advanced stage and poor survival of ovarian cancer patients, 73 and Mcl-1 is coexpressed with IL-6 in cervical cancer. 74 Bfl-1/ A1
75 and bcl-X both are target genes of nuclear factor (NF)-kappaB, and participate in the survival of Hodgkin and ReedSternberg cells in which NF-kappaB is constitutively activated. 76 Bfl-1/A1 expression has also been detected in some cases of colorectal adenoma. 77 In view of the large body of data implicating antiapoptotic Bcl-2 family members in poor patient prognosis and chemoresistance, there is considerable need to develop agents that specifically target these proteins. In fact, in the past few years, several strategies and novel agents have been developed that selectively target Bcl-2 and Bcl-X L (Figure 2 ). For some of these agents, testing is currently being pursued at the level of clinical trials, and significant positive benefits have been demonstrated. 79 who used a 20-mer oligonucleotide (TI-AS) directed against the translation initiation site of Bcl-2 mRNA. Phosphorothiorate derivatives of the same oligonucleotide (a variation of the phosphodiester backbone in which one nonbridging oxygen atom in the internucleotide bond is replaced by a sulfur atom) exhibited enhanced ability to inhibit leukemic cell growth. 79 The phosphorothiorate antisense molecule killed leukemic cells directly, but was more effective when used in combination with chemotherapeutic agents. 80, 81 The Bcl-2 antisense molecule that is currently being tested in clinical trials is named G3139 (also referred to as Genasense), and is an 18-nucleotide sequence that is complementary to the first six codons of Bcl-2 mRNA. In early studies, G3139 displayed cell-killing effects against t(14;18)-containing lymphoma cells.
82 G3139 also exhibited a sensitizing effect on lymphoma cells against cytosine arabinoside and methotrexate, indicating a potential usefulness of this antisense molecule in combination therapy. 83, 84 In a separate study, G3139 led to decreased levels of Bcl-2 protein, and enhanced sensitivity to doxorubicin and dexamethasone, in malignant cells derived from multiple myeloma patients. 85 The utility of in vivo Bcl-2 antisense treatment was demonstrated when pretreatment with a 20-mer antisense (against the translation initiation site) dramatically inhibited the establishment of human B-cell lymphoma in a mouse model system. 86 In addition, in vivo treatment with Bcl-2 antisense lowered the dose of cyclophosphamide required to eradicate human B-cell lymphoma cells in a SCID mouse model. 87 In an attempt to develop more potent Bcl-2 antisense agents, Ziegler et al 88 88 and has been successfully employed to induce apoptosis in the lymphocytes of B-CLL patients. 89 Interestingly, treatment of cells with ODN 2009 not only reduced the expression of Bcl-2 but also induced upregulation of Bax, 89 and increased the sensitivity of leukemic cells to fludarabine treatment.
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G3139 (Genasense) was the first Bcl-2 antisense molecule to be employed in clinical trials of non-Hodgkin's lymphoma (NHL) patients. In a phase I clinical trial of relapsing, Bcl-2-positive NHL, subcutaneous infusion of G3139 antisense decreased the levels of Bcl-2 protein in two of five patients, and showed no toxicity other than inflammation at the site of infusion. 91 In addition, G3139 sensitized seven of eight patients to chemotherapy treatment, six of whom achieved partial remission, and one who achieved complete remission. 91 Similarly, in a phase I clinical study of 21 patients with recurring NHL, administration of G3139 antisense downregulated Bcl-2 levels in seven of 16 patients without generating sequence-specific toxicity. 92 However, in both of these clinical trials, Bcl-2 antisense exhibited some nonspecific toxicity, which was attributed to the phosphorothiorate backbone structure of the antisense molecule. 91, 92 In a different phase I study, G3139 was employed in combination with fludarabine, cytarabine, and granulocyte colony-stimulating factor (G-CSF) for patients with relapsed or refractory AML or ALL. 93 Of the 17 AML and three ALL patients given G3139 in combination with fludarabine, cytarabine, and G-CSF, six achieved complete remission (five AML and one ALL) and three achieved incomplete remission (two AML and one ALL). G3139 is also currently being employed in clinical trials of patients with relapsed or refractory CLL, and combination of G3139 with dexamethasone is under investigation in phase I-III studies of multiple myeloma (www.clinicaltrials.gov).
The application of Bcl-2 antisense technology to nonhematological cancers also may prove beneficial. In phase I-II clinical trials of human malignant melanoma, G3139 exhibited a chemosensitizing effect, 94 consistent with G3139 enhancement of drug sensitivity in a SCID mouse model of human melanoma. 95 In prostate cancer, where Bcl-2 overexpression has been correlated with progression to androgen-independence, preclinical testing demonstrated an ability of Bcl-2 antisense (G3139) to delay the progression to androgenindependence in the Shionogi mouse 96 and human LNCaP 97 prostate tumor models. The antitumor activity of G3139 also synergized with chemotherapeutic agents in these prostate tumor models. 98,99 G3139 alone, 100 or in combination with chemotherapy, 101, 102 was well tolerated in hormone-refractory prostate cancer in phase I clinical trials, and the effects of G3139 appear to synergize with doxorubicin. 103 Bcl-2 antisense was also effective against human bladder transitional cell carcinoma, 104 while colon cancer was more responsive to combined treatment with antisense Bcl-2 and antisense protein kinase A type I (PKAI) in a human colon cancer mouse model. 105 The ability of Bcl-X L to confer resistance to chemotherapy drugs is well established in cell line models. 106 These effects are mimicked in Bcl-X L -overexpressing hematological malignancies such as AML 59 and multiple myeloma. 38, 61 Bcl-X L has been reported to participate in Bcr-Abl-mediated drug resistance, since Bcl-X L antisense oligonucleotide increased the susceptibility of Bcr-Abl-HL-60 cells to staurosporine. 107 Treatment of cell lines representing human prostate cancer, 108 bladder cancer, 109 colon cancer, 110 hepatoma, 111 gastric cancer, 112 and pancreatic carcinoma 113 with Bcl-X L antisense sensitized these cells to apoptosis. In MCF7 breast cancer cells, where Bcl-X L is expressed at high levels, antisense-mediated downregulation of Bcl-X L expression directly induced apoptosis. 114 A selective induction of apoptosis was also observed in two NSCLC lines (but not in SCLC cell lines) after treatment with Bcl-X L antisense. 1 Importantly, since the cellular ratio of the two splicing products of the bcl-x gene, Bcl-X S (proapoptotic) and Bcl-X L (antiapoptotic), may dictate sensitivity to death stimuli, 12 then altering the ratio in favor of proapoptotic Bcl-X S should facilitate (normally undetectable) and a decrease in Bcl-X L (present at high levels), and sensitized these cells to chemotherapeutic agents and UV radiation. 115 In attempting to maximize the impact of antisense therapies, it is important to consider the expression profile and prognostic significance of Bcl-2 and Bcl-X L in the particular disease, or disease stage, being treated. Thus, in diseases such as malignant melanoma, prostate cancer, and SCLC where Bcl-2 and Bcl-X L are co-overexpressed, simultaneous downregulation of their mRNAs should represent a more effective strategy than targeting either molecule alone. Successful downregulation of two distinct gene products has been achieved by either of two approaches: (a) combined treatment with two separate antisense molecules, 116, 117 or (b) treatment with a single antisense molecule targeting both Bcl-2 and Bcl-X L . 117, 118 Simultaneous downregulation of Bcl-2 and Bcl-X L has proven useful in SCLC, 118, 119 melanoma. 117, 120 and prostate cancer 116 cell lines. The antitumor activity of bispecific antisense has been demonstrated in mouse xenograft models of colon and breast cancer. 121 Recently, antisense-mediated downregulation of Mcl-1 was used to establish a critical role for Mcl-1 in the survival of multiple myeloma cells. 72 In contrast to Bcl-2 antisense, which acts to sensitize multiple myeloma cells to dexamethasone, antisense Mcl-1 alone was sufficient to promote apoptosis in these cells. 122 Targeting the function of Bcl-2 and Bcl-X L : key insights gained from studying the structures of Bcl-2 family members While antisense-based technologies are aimed at reducing the expression of target proteins, alternative strategies for targeting cell death inhibitors are directed at crippling the antiapoptotic function of these proteins through the use of inhibitory peptides or small molecules. Efforts to inhibit the function of antiapoptotic proteins have been facilitated by a detailed knowledge of the structural organization of Bcl-2 family members ( Figure 1 ). All members of the Bcl-2 protein family contain at least one of four conserved motifs known as Bcl-2 homology (BH) domains (BH1, BH2, BH3, and BH4). In addition to the presence of BH domains, most of the antiapoptotic molecules possess a carboxyl-terminal membrane-anchoring domain (TM). Antiapoptotic members such as Bcl-2 and Bcl-X L contain all four BH domains, along with the transmembrane domain. In Mcl-1L, the BH4 domain is missing. Multidomain proapoptotic proteins such as Bax and Bak contain all but the BH4 domain. A second subgroup of proapoptotic proteins, known as 'BH3-domain only' proteins (eg. Bad and Bid), consists of molecules that contain only the BH3 domain and lack other BH domains. Proapoptotic proteins such as Bcl-X S and Mcl-1S, representing alternatively spliced forms of the bcl-x and mcl-1 genes, respectively, lack BH1 and BH2 domains. Additionally, Mcl-1S lacks a transmembrane domain.
The tertiary structures of Bcl-2 123 and Bcl-X L 124 are composed of two core hydrophobic alpha helices (a5 and a6) surrounded by five amphipathic helices (a1,a2,a3,a4 and a7). Proapoptotic Bax also possesses the same general structural organization. 125 Early crystallographic and NMR studies revealed structural similarities between Bcl-X L and pore-forming bacterial toxins. 124, 126 Coupled with the known role of Bcl-2 proteins in regulating mitochondrial cytochrome c release during apoptosis, 127, 128 this information stimulated examination of the ion channel-and pore-forming properties of Bcl-2 family members. Such investigations demonstrated that Bcl-2 129, 130 and Bcl-X L , 131 as well as proapoptotic Bax 130, 132 have the capacity to form ion channels in synthetic lipid membranes. Other studies have shown that proapoptotic molecules such as Bax undergo oligomerization in the mitochondrial membrane during apoptosis signal transduction, forming large pore-like structures. 133, 134 The pores formed by oligomerized Bax appear to be large enough to allow the passage of molecules such as cytochrome c, although it remains controversial whether this is the mechanism of cytochrome c release from mitochondria. 135 Functional studies of Bcl-2 family members have revealed that the actions of these proteins are tightly regulated by proteinprotein interactions with other members of the family. In particular, heterodimerization between pro-and antiapoptotic molecules is critically important. 16, [136] [137] [138] In the presence of high levels of antiapoptotic proteins such as Bcl-2 and Bcl-X L , as is commonly seen in some forms of cancer, the ratio of proapoptotic to antiapoptotic molecules becomes unfavorable for execution of cell death. However, recent evidence indicates that agents which disrupt heterodimerization between anti-and proapoptotic molecules can promote cell-killing. Thus, a number of investigators have set out to identify or design molecules that can disrupt these heterodimerization interactions. The ability to devise such agents has been aided by studies that have delineated the protein interaction domains present in anti-and proapoptotic molecules. Mutational analyses have disclosed that Bax/Bcl-2 heterodimerization requires the BH1, BH2, BH3, and BH4 regions of Bcl-2, [139] [140] [141] and all four of these domains contribute to the cell survival functions of Bcl-2.
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By contrast, only the BH3 region of Bax or Bak is required for heterodimerization with Bcl-2 or Bcl-X L . [143] [144] [145] [146] [147] Furthermore the BH3 domain is required for the proapoptotic activity of Bax and Bak, as well as the 'BH3-domain only' proteins. [143] [144] [145] 147, 148 Structural studies have revealed that the BH1, BH2, and BH3 domains in antiapoptotic proteins are folded to create an elongated hydrophobic pocket that serves as a docking site for the amphipathic BH3 domain of a proapoptotic molecule. 124, 149, 150 Hence, this pocket is termed the BH3 binding pocket. Experimental mutation of specific residues lining the BH3 binding pocket has generated loss-of-function mutants that are unable to suppress cell death. These structure/function studies are proving useful in guiding the design of molecules that fit into the BH3 binding pocket, disrupting heterodimerization interactions and neutralizing the antiapoptotic effects of Bcl-2 and Bcl-X L . In addition, studies using synthetic BH3 domain peptides have helped in understanding the molecular interactions involved in ligand-pocket fitting. 149, 150 Taken together, mutagenesis studies, and structural and computational analyses have directed current strategies for neutralizing Bcl-2 and Bcl-X L function toward employing (1) synthetic peptides resembling BH3 domains of proapoptotic molecules, and (2) small organic molecules that efficiently fit into the hydrophobic, receptor-like pocket on the surface of antiapoptotic molecules. Both BH3-domain-based peptides and small organic molecules hold considerable promise for the treatment of cancers overexpressing Bcl-2 or Bcl-X L .
BH3 domain peptides
Several studies have investigated the capacity of peptides, representing BH3 domain sequences, to affect heterodimerizaTargeting cell death inhibitors in the Bcl-2 protein family S Shangary and DE Johnson tion interactions among Bcl-2 family members, and to sensitize cells to apoptosis. BH3 peptides derived from proapoptotic Bax and Bak inhibit in vitro heterodimerization interactions between Bax and Bcl-2, as well as heterodimerization between Bax and Bcl-X L in plate binding assays. 146 Peptides representing the Bad BH3 domain have exhibited inhibitory activity towards Bax/Bcl-X L and Bad/Bcl-X L interactions in similar assays. 148 In solution binding assays, Bad BH3 peptide demonstrated selective disruption of Bax/Bcl-X L , but not Bax/Bcl-2, while Bax BH3 peptide disrupted both Bax/Bcl-2 and Bax/Bcl-X L heterodimerization interactions. 151 By contrast, Bcl-2 BH3 peptide showed no ability to disrupt heterodimerization. 151 The induction of apoptosis signal transduction by BH3 peptides derived from proapoptotic proteins was first studied in cell-free extracts of Xenopus eggs. 152 In this system, both Bax and Bak BH3 peptides, but not Bcl-2 BH3 peptide, displayed apoptotic activity, as measured by caspase activation. 152 Subsequent studies investigated the ability of BH3 peptides to promote apoptosis in cell-free extracts from mammalian cells. The release of cytochrome c from mitochondria, which is critical for caspase activation, has commonly been used as a marker of apoptosis induction in these studies. 153, 154 Bax BH3 peptide, as well as full-length Bax protein, was found to induce cytochrome c release and loss of mitochondrial transmembrane potential (DC m ) from purified mitochondria. 151, [155] [156] [157] For studies involving treatment of whole cells with peptides, it has been necessary to employ techniques that enable efficient intracellular delivery of the peptide molecules. Recently, peptide sequences derived from antennapedia protein of Drosophila, 158 TAT protein of human immunodeficiency virus-1, 159, 160 and the VP22 structural protein 161, 162 of herpes simplex virus have been found to facilitate translocation of macromolecules across cell membranes. In addition, conjugation with fatty acids 163 or electroporation 164 are other means to make BH3 peptides cell permeable. The 16-amino-acid antennapedia peptide (ANT) transduction domain has frequently been used to facilitate the delivery of BH3-domain peptides into cells. ANTBak BH3 peptide rapidly achieved entry into HeLa cells and produced an apoptotic response within 2-3 h. 165 In addition, this peptide converted Bcl-X L -overexpressing HeLa cells from a Fas-refractory to a Fas-sensitive phenotype. 165 Wang et al 163 rendered Bad BH3 peptide (residues 140-165) cell permeable by fusion with decanoic acid. Treatment with this fatty acidconjugated peptide led to apoptosis in Bcl-2-and Bcl-X Loverexpressing cells; however, normal lymphocytes remained unaffected. 163 Administration of decanoic acid-Bad BH3 peptide into SCID mice that were challenged with HL-60 cells led to an increased mean survival time. 163 A different study showed that unconjugated Bad BH3 peptide was capable of killing Jurkat T-leukemic cells overexpressing either Bcl-X L or Bcl-2 following introduction into cells using a cationic lipid delivery system. 151 Interestingly, Bad BH3 produced a higher apoptotic response in Bcl-X L -overexpressing Jurkat cells than in Jurkat cells overexpressing Bcl-2. 151 This is consistent with a higher affinity of full-length Bad and Bad BH3 peptide for Bcl-X L . 136, 148, 166 In related studies, introduction by electroporation of Bax and Bak BH3 peptides into PC-3 prostate cancer cells disrupted intracellular Bak/Bcl-2 interactions and resulted in apoptotic death. 164 Despite impressive induction of apoptosis by BH3 peptides derived from proapoptotic molecules, questions remain regarding the mechanism of peptide-mediated killing. A key question is whether the killing is due to peptide-mediated disruption of heterodimerization interactions or direct activation of proapoptotic proteins, or is simply due to the alpha-helical content of the BH3 domain sequence. The disruption of heterodimerization interactions by BH3 peptides has been demonstrated in a number of cell-free and whole-cell experiments. 146, 148, 151, 164, 167 Furthermore, the ability of a peptide to promote apoptosis in cells overexpressing either Bcl-2 or Bcl-X L generally correlates with the relative affinity of the peptide for these proteins. For example, Bad BH3, which shows a higher affinity for Bcl-X L , is more efficient at killing Bcl-X L -overexpressing cells than Bcl-2-overexpressing cells. 151 Perhaps, the most definitive results, however, have come from a recent report by Letai et al. 167 According to this study, Bid and Bim BH3 peptides directly interact with proapoptotic Bax or Bak, inducing oligomerization and the onset of apoptosis signaling. On the other hand, Bad and Bik BH3 peptides interact with Bcl-2 (and presumably Bcl-X L ) causing displacement, and activation, of any bound proapoptotic molecules. 167 Still other studies have suggested that BH3 peptides promote death simply because of their high alpha-helical content, as is the case for the artificial peptide (KLALAK) 2 , which acts to disrupt the negatively charged mitochondrial membrane. 168, 169 In this regard, a mutated Bad BH3 peptide which retains alpha-helical content, but is no longer able to bind Bcl-2, is capable of promoting apoptosis in Bcl-2-overexpressing cells. 169 By contrast, a non-helical mutant demonstrated no toxicity. Additional studies suggest that BH3 peptides with higher alpha-helical content may be more potent because they exhibit higher affinity for antiapoptotic proteins. 150 Attempts to develop peptide-based agents as efficient anticancer agents face several challenges, since peptides are typically high molecular weight compounds, and are subject to poor solubility, limited cellular permeability, and proteolytic degradation. However, the current use of peptide-based drugs for the treatment of a variety of diseases lends support for the development of BH3 peptides as novel anticancer drugs. Furthermore, most current studies employ protein transduction domains (PTDs) such as ANT and TAT to facilitate entry into cells. The identification of novel PTDs that facilitate permeability across membranes of diverse cell types is critical for increasing the utility of peptide-based agents. The enhancement of BH3 peptide stability through chemical modifications such as cyclization and the development of peptidomimetics represent other promising avenues for improving the drug-like properties of these peptides.
Small molecule inhibitors of Bcl-2 and Bcl-X L function
Recently, intensive efforts have been made to identify or design small organic molecules capable of antagonizing Bcl-2 or Bcl-X L function. Small organic molecules offer several potential advantages over peptide-based drugs, in that they can be selected and quickly refined for optimal solubility, cell permeability, stability, binding affinity, and activity. Moreover, recent advances have made it possible to rapidly screen large numbers of compounds in existing chemical libraries if suitable assays are employed. Modification and optimization of promising lead compounds can then be accomplished using medicinal or combinatorial chemistry. In recent years, several small molecule inhibitors have been identified by screening existing libraries of natural products or chemical compounds using Bcl-2 or Bcl-X L plate binding assays. In addition, computational methods and knowledge of the three-dimensional structures of Bcl-2 and Bcl-X L have been used as a basis for the design of small molecule inhibitors.
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Tetrocarcin A: Tetrocarcin A (TC-A; Figure 3 ) was identified by screening a library of natural products for compounds capable of inhibiting the antiapoptotic functions of Bcl-2.
170 TC-A was originally identified as an antibiotic from Actinomycete strain DO-11 (KY11091) and possesses selective antimicrobial activity against Gram-positive bacteria. 171 Subsequently, TC-A was found to exhibit antitumor activity. 172, 173 TC-A treatment enhanced the sensitivity of Bcl-2-overexpressing cells to Fas, tumor-necrosis factor (TNF), and staurosporine. 170 TC-A also abrogated the suppressive effects of Bcl-X L overexpression, rendering Bcl-X L -overexpressing cells amenable to Fas-mediated apoptosis. 170 In an effort to dissociate the Bcl-2-inhibitory functions of TC-A from its antimicrobial activity, several derivatives of TC-A were synthesized and shown to be as effective as the parent molecule at inhibiting the growth of HeLa/Bcl-2 cells. 174 Treatment with such derivatives in combination with anticancer agents should prove useful in the treatment of chemotherapy-resistant human tumors that overexpress Bcl-2.
Some cell type specificity for TC-A action has been reported. For example, although TC-A alone is capable of killing T-ALL cells, 175 no direct apoptosis-inducing activity is seen in HeLa cells. 170 Overexpression of Bcl-2 in T-ALL cells resulted in delay, but not complete inhibition, of TC-A-induced death. The effects of TC-A in T-ALL cells were accompanied by loss of DC m , cleavage of Bid and Bax, release of cytochrome c from mitochondria, activation of caspase proteases, and induction of HSP 70 and HSP 110. 175 Presently, however, the immediate intracellular target of TC-A remains unknown.
Antimycin A: Antimycin A was identified by testing various inhibitors of mitochondrial respiration for their ability to overcome the effects of Bcl-X L overexpression. 176 Subsequently, molecular docking studies predicted the binding of antimycin A to the hydrophobic surface pocket in Bcl-X L and Bcl-2.
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The binding to Bcl-2 has been verified in fluorescence spectroscopies assays. 176, 177 Antimycin A3 (Figure 4) , one of the subspecies of antimycin A, is an inhibitor of mitochondrial electron transport at complex III and has been reported to display toxicity toward Bcl-2 and Bcl-X L -overexpressing hepatocyte cell lines. 176, 177 Cell death resulting from antimycin A 3 occurs independently from inhibition of cellular respiration since 2-methoxy antimycin A 3 , an antimycin A 3 derivative lacking these inhibitory properties, retains the ability to kill cells. 176 Strikingly, Bcl-X L -overexpressing murine hepatocytes, cells that are normally resistant to doxorubicin, cisplatin, and TNF, were shown to be hypersensitive to antimycin A 3 treatment. 176 Moreover, hepatocytes that overexpress Bcl-X L showed greater antimycin A 3 -induced loss of mitochondrial membrane potential compared to cells that express low levels of Bcl-X L . However, the hypersensitivity of Bcl-X L -overexpressing cells to antimycin A 3 is not a universal phenomenon since Bcl-X L -overexpressing FL5.12 pro-B lymphoid cells (unlike Bcl-X Loverexpressing hepatocytes) failed to exhibit loss of DC m and mitochondrial swelling following antimycin A 3 treatment. 176 It remains unclear whether other cellular factors beyond Bcl-X L or Bcl-2 may bind antimycin A 3 and determine cellular sensitivity to this compound.
HA14-1: HA14-1 ( Figure 5 ) was the first small organic molecule capable of binding Bcl-2 to be identified by computer-aided screening of a chemical library (193,833 compounds were screened).
178 HA14-1 was identified by screening for molecules that could bind to the BH3 binding pocket of Bcl-2. Subsequent fluorescence polarization assays verified that HA14-1 competed with Bak BH3 peptide for binding to Bcl-2. Apoptosis induced by HA14-1 in HL-60 cells is characterized by activation of caspase proteases and loss of DC m . 178 In another study, HA14-1 was found to enhance the apoptotic effects of mitogen-activated protein kinase kinase (MEK) inhibitors in leukemic cell lines. 179 Based on this observation, combined drug treatment to target Bcl-2 and MEK/MAPK pathways has been suggested for AML patients with constitutive expression of MAPK and unfavorable Bax/Bcl-2 ratios.
BH3I compounds: A series of seven compounds called BH3 inhibitors (BH3Is) were identified as competitors of Bak BH3 binding to Bcl-X L in a random screening approach. 180 The seven compounds fall into two structurally distinct categories: three Figure 3 Chemical structure of TC-A. Chemical structures of antimycin A 3 and 2-methoxy antimycin A 3 .
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Targeting cell death inhibitors in the Bcl-2 protein family S Shangary and DE Johnson are structural relatives of BH3I-1, and two are related to BH3I-2 (Figure 6a and b) . The BH3I compounds were identified by employing fluorescence polarization assays to screen a library consisting of 16,320 compounds. The cytotoxicity of each inhibitor compound correlated with its ability to displace BH3 peptide from Bcl-X L in vitro and to disrupt intracellular Bax/ Bcl-X L interactions. 180 Induction of apoptosis by BH3I-1 and BH3I-2 in Jurkat cells was accompanied by cytochrome c release, and caspase-8 and -9 activation. Higher concentrations of BH3I-1 and BH3I-2 were able to overcome the protective effects of Bcl-X L in Jurkat and FL5.12 cells. In addition, the combination of interleukin-3 (IL-3) withdrawal and treatment with BH3Is enhanced FL5.12 apoptotic death. The BH3I compounds have been shown to disrupt the following intracellular heterodimerization interactions: Bax/Bcl-X L , Bad/Bcl-X L , and Bad/Bcl-2. In whole-cell assays, disruption of these heterodimerization interactions by BH3Is occurred prior to the death of the cell. 180 Lugovskoy et al 181 showed that the cell-killing activities of BH3I molecules can be predicted using a novel molecular modeling method analyzing BH3I/Bcl-X L complexes, and that the killing activities correlated with the experimentally determined affinities of the compounds for Bcl-X L . This modeling approach, based on the 'shape complementarity' of the protein-compound complex, was subsequently employed in a virtual screen for BH3I homologs in the Chemnavigator (www.chemnavigator. com) and Chembridge (www.hit2lead.com) compound libraries. This screening resulted in identification of another molecule, BH3I-1SCH 3 , which bound to Bcl-X L in in vitro assays (Figure 6c) . 181 In another report, Bcl-2 structure-based screening of the NCI organic compound database (over 2 million compounds) yielded seven organic molecules (compounds 5, 6, 7, 8, 9, 10, and 11) that exhibited binding to Bcl-2 in fluorescence polarization assays. 182 Of these seven molecules, compound 6 (Figure 6d ) was found to be the most effective at inducing apoptosis in MDA-MB231 breast cancer and HL-60 leukemia cells. 182 
Perspectives
Promising results from clinical trials with G3139 (Genasense) Bcl-2 antisense strongly support the strategy of targeting antiapoptotic molecules in the treatment of cancer. Antisense approaches directed against antiapoptotic proteins are likely to be most effective when combined with conventional apoptosisinducing stimuli such as chemotherapy drugs and radiation. Moreover, it should be possible to provide patient-specific optimization of antisense therapies by first characterizing the repertoire of antiapoptotic molecules expressed in the malignant cells of the patient. Depending on the type of cancer, the stage of disease, and the individual patient, it may be necessary to target mRNAs for multiple antiapoptotic proteins.
Although less developed in terms of clinical testing, the new wave of pharmacologic inhibitors of Bcl-2 and Bcl-X L function is cause for considerable optimism. Chemical structure of HA14-1. Targeting cell death inhibitors in the Bcl-2 protein family S Shangary and DE Johnson knowledge regarding the structures of Bcl-2 and Bcl-X L , raise the prospect that many more inhibitors will soon be discovered and available for testing. Through the application of combinatorial and medicinal chemistry, it should be possible to optimize these compounds for specificity, activity, solubility, and cell permeability. As is the case for antisense molecules, pharmacologic inhibitors will most likely find their greatest effectiveness when used in combination with chemotherapy drugs, radiation, or other targeting agents. With respect to the latter, the combination of antisense to reduce expression and a pharmacologic inhibitor to reduce function may provide a 'double whammy' to cells overexpressing antiapoptotic proteins, rendering them exquisitely sensitive to conventional therapies.
